Angelexo Secures Tens of Millions in Pre-A Funding to Accelerate Industrialization of Intelligent Neurorehabilitation Robots

VCBeat (WeChat: vcbeat) has learned that Angele Technology (Hangzhou) Co., Ltd. (hereinafter referred to as “Angele Technology”), an emerging smart robotics company focusing on neurological rehabilitation, has announced the completion of its Pre-A financing round, raising tens of millions of yuan. The round was led by October Capital, with Shanghai Xuyuan as a participating investor. The funds will be used for the research and development of essential neurological rehabilitation medical products, clinical trials, and commercial promotion.

Anjielai Technology was established in December 2017 and is aAn Intelligent Robotics Company Focused on Brain Science Applications, is a national high-tech enterprise founded by leading experts in robotics, artificial intelligence, and biomedical sciences, along with senior clinical medicine specialists. Headquartered in Hangzhou, Zhejiang, the company has established branches and subsidiaries in Beijing and Zhengzhou, Henan, respectively, as well as an overseas business division in Seattle, USA, thereby initially establishing a global R&D, manufacturing, sales, and service network.

The company focuses on the intelligent robotics sector, addressing critical market needs by dedicating itself to the research and development of key core technologies for industrialization and establishing an industrialization technology platform. The company’s independent intellectual property rights includeNon-invasive Brain-Computer Interface, Human-Machine Intelligent Interaction, Autonomous Machine Learning, Redundant Sensor Fusion, Non-invasive Sensing of Bone and Muscle Metabolic Information, Bionic Exoskeleton Designand other innovative technologies. The company boasts strong technological innovation capabilities and has been successively recognized as a technology-based small and medium-sized enterprise (SME) at both the national level and in Zhejiang Province. In 2021, it was accredited as a National High-Tech Enterprise and independently undertook a key research and development project under the Zhejiang Provincial Key R&D Program. Its LiteStepper™ single-limb lower extremity rehabilitation training robot productApproved by the National Medical Products Administration for classification as a Class II innovative medical device. Anjielai Technology currently holds intellectual property rightsOver 70 items, including granted/filed invention patents20+ items。

Currently, leveraging its proprietary intelligent robotics platform technology, the company has developed specialized solutions for neurological rehabilitation.Product Series Including Intelligent Rehabilitation Robots for Single Lower Limb and Bilateral Ankle-FootBy inducing active rehabilitation, the robot intelligently assesses the patient’s movement intentions and characteristics, guiding them through bilateral coordinated motor relearning training. This approach efficiently promotes functional reconstruction of the central nervous system, enabling patients to gradually restore normal neuromuscular control and achieve personalized, systematic, and precise active rehabilitation. Building on this foundation, the company provides intelligent rehabilitation products to rehabilitation institutions at all levels, as well as to patients and their families. These products include intelligent rehabilitation robots, smart devices for physical and occupational therapy, and digital information management systems for rehabilitation medical care. This comprehensive solution benefits patients with multi-disciplinary neurological impairments, such as those resulting from traumatic brain injury, cerebrovascular accidents, and cerebral palsy, thereby delivering a complete suite of intelligent neurorehabilitation services.

Currently, Anjielai Technology hasand Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center) Affiliated to Tongji University, the First Affiliated Hospital of Zhejiang University, the Second Affiliated Hospital of Zhejiang University, Hangzhou First People's Hospital, Jiaxing First Hospital, the Rehabilitation Hospital of Zhengzhou University (the Fifth Affiliated Hospital), and the Rehabilitation Centre at the University of British Columbia, CanadaEstablished clinical research/trial partnerships with dozens of medical institutions both in China and abroad, jointly promoting academic research and clinical application of intelligent rehabilitation robots on a global scale.

For this financing round,Dr. Li Luya, Founder of Anjielai Technologystated: “AngelTech is actively responding to the national call to comprehensively enhance the independent innovation capabilities of domestically produced high-end medical devices. We are deeply focused on addressing the rigid demands and urgent pain points in the clinical field of rehabilitation medicine. Leveraging our significant advantages in product innovation and R&D, as well as our proprietary intelligent robotics platform technology, we are vigorously advancing the development of various intelligent rehabilitation robotics products. We will integrate relevant industry resources to accelerate clinical trials and industrialization, further broaden our product pipeline, reduce the workload of healthcare professionals, and enable patients to benefit from innovative intelligent rehabilitation medical care. We sincerely appreciate the recognition and support from outstanding investors such as Shiyue Capital and Shanghai Xuyuan. Together with elites from all sectors of society, we will jointly create and welcome a new milestone in the large-scale application of intelligent rehabilitation robots.”

Gong Hanting, Partner at October Capital“It stated: ‘Intelligent rehabilitation medicine is one of the key areas of long-term focus for Shiyue Capital. Anchored in the Chinese market, which has the largest global demand for rehabilitation services, Angelai Technology, as a leading domestic manufacturer of intelligent robots, has laid a solid foundation for safe, precise, efficient, and intelligent rehabilitation training for patients through its series of intelligent rehabilitation robots, which are based on the deep integration of clinical rehabilitation medicine and artificial intelligence. We are delighted to partner with Angelai Technology to jointly develop high-end medical devices for intelligent neurological rehabilitation, improve the efficiency of rehabilitation care, and enhance patients’ quality of life. We will continue to deepen our collaboration with Dr. Li Luya and his team, leveraging our industry resource advantages to make Angelai Technology’s outstanding products accessible to more users, thereby helping to advance China’s intelligent rehabilitation medicine sector to new heights.’”

Qin Biao, Executive Partner of Shanghai Xuyuan“We believe that there is still a vast unmet market in the field of neurological rehabilitation waiting to be tapped. Advanced theories of neurological rehabilitation are difficult to fully apply in clinical practice due to limitations of existing equipment and technology, while artificial intelligence (AI) technologies based on neuroscience can meet these rigid clinical demands. We are delighted to see Angelai Technology perfectly integrate modern rehabilitation theory, AI, and robotics, creatively developing multiple globally leading intelligent rehabilitation robot products. As Angelai Technology’s products continue to enter the market, a wave of new AI-driven products based on neuroscience will emerge in the field of rehabilitation medicine, leading rehabilitative therapy into a new era of intelligence. We will engage in deep collaboration with the Angelai Technology team across multiple levels, leveraging our accumulated industry experience and resources to provide comprehensive support for Angelai Technology’s global expansion.”

Shiyue Capital is a fast-growing, emerging private equity investment management firm founded by former senior executives of leading Chinese securities firms and core members of their equity investment and investment banking teams. Shiyue Capital operates three management platforms, currently manages more than 10 private equity funds, and has assets under management exceeding RMB 3 billion. Since 2016, it has invested in nearly 50 projects, with 22 portfolio companies successfully listed on China’s A-share market (including those approved but not yet issued), and over 10 prospective IPO candidates currently in the application process.

Shanghai Xuyuan Enterprise Consulting Management Center (Limited Partnership) was co-founded by a group of investors with many years of experience in equity investment within the medical industry. Mr. Qin Biao, the managing partner, previously served as General Manager of the Biopharmaceutical Division at Yingke Capital, where he led his team in investing in more than ten projects, including well-known pharmaceutical companies such as Arno Therapeutics and PegBio. Most team members have over ten years of work experience at renowned multinational corporations such as Bayer, Novartis, and Merck & Co., and possess entrepreneurial experience in the biopharmaceutical sector, bringing deep industry insights and extensive industrial resources.